212 related articles for article (PubMed ID: 20567125)
1. [A case of Complete Response(CR)to combination therapy of S-1 and Gemcitabine(GEM)for unresectable pancreatic cancer].
Miyagawa K; Yata Y; Yamaoka N; Sagara Y
Gan To Kagaku Ryoho; 2010 Jun; 37(6):1145-7. PubMed ID: 20567125
[TBL] [Abstract][Full Text] [Related]
2. [S-1+gemcitabine (GEM) therapy was effective in a case of unresectable pancreatic head carcinoma].
Takada J; Okuda K; Kenno S; Shimada S; Oba G; Shimokuni T; Aoki T; Hamada H
Gan To Kagaku Ryoho; 2008 Nov; 35(12):2120-2. PubMed ID: 19106543
[TBL] [Abstract][Full Text] [Related]
3. [A case of advanced pancreatic cancer responding well to S-1/gemcitabine combination therapy after gemcitabine therapy].
Kuji M; Yamamoto Y; Tani C; Kenno S; Kobayashi T
Gan To Kagaku Ryoho; 2011 May; 38(5):853-5. PubMed ID: 21566453
[TBL] [Abstract][Full Text] [Related]
4. [S-1+gemcitabine (GEM) therapy effective in a case of pancreatic body cancer with multiple liver metastasis].
Fukui H; Kou C; Matsumoto T; Matsumoto M
Gan To Kagaku Ryoho; 2010 Sep; 37(9):1775-8. PubMed ID: 20841945
[TBL] [Abstract][Full Text] [Related]
5. [A case of complete response of gemcitabine (GEM) monotherapy-refractive liver metastatic pancreatic cancer treated with GEM+S-1 combined chemotherapy].
Hatata T; Takaya S; Taniguchi K; Naka T; Kondo A; Ikeguchi M
Gan To Kagaku Ryoho; 2011 Jan; 38(1):109-12. PubMed ID: 21368469
[TBL] [Abstract][Full Text] [Related]
6. [A case of recurrent pancreatic cancer with lung metastasis responding to S-1 combined gemcitabine chemotherapy].
Fukada I; Ikeda H; Yamaguchi K; Okabe M; Tsuruta A; Morimoto Y; Kawamoto K; Sano K; Paku T; Imai S; Yoshida Y; Ito T; Ogasahara K
Gan To Kagaku Ryoho; 2009 Oct; 36(10):1733-6. PubMed ID: 19838037
[TBL] [Abstract][Full Text] [Related]
7. Gemcitabine and S-1 combination chemotherapy versus gemcitabine alone for locally advanced and metastatic pancreatic cancer: a meta-analysis of randomized controlled trials in Asia.
Li Y; Sun J; Jiang Z; Zhang L; Liu G
J Chemother; 2015 Aug; 27(4):227-34. PubMed ID: 25790948
[TBL] [Abstract][Full Text] [Related]
8. [Usefulness of S-1/gemcitabine combination therapy for advanced pancreatic cancer].
Hara T; Nagata M; Yamashita Y; Fujimoto K; Muraki Y; Yasuda Y; Kurahashi T
Gan To Kagaku Ryoho; 2008 Jul; 35(7):1233-7. PubMed ID: 18633271
[TBL] [Abstract][Full Text] [Related]
9. [Response in a case of inoperable bile duct cancer treated by combined chemotherapy of S-1 and gemcitabine].
Akiyama N; Ayata S; Maruyama Y; Tsukada Y
Gan To Kagaku Ryoho; 2010 Aug; 37(8):1591-3. PubMed ID: 20716894
[TBL] [Abstract][Full Text] [Related]
10. Retrospective study of gemcitabine plus S-1 versus gemcitabine alone in cases with unresectable advanced pancreatic cancer.
Suzuki S; Ozaki Y; Saida S; Kaji S; Koike N; Harada N; Hayashi T; Suzuki M
Hepatogastroenterology; 2013 Jun; 60(124):916-20. PubMed ID: 23478143
[TBL] [Abstract][Full Text] [Related]
11. [Effective multidisciplinary therapy mainly using S-1+ gemcitabine (GEM) for a case of pancreatic body cancer with multiple liver metastases].
Fukui H; Kou C; Fujioka M
Gan To Kagaku Ryoho; 2012 Nov; 39(11):1727-31. PubMed ID: 23152029
[TBL] [Abstract][Full Text] [Related]
12. [Gemcitabine in combination with S-1 or UFT in patients with advanced pancreatic cancer].
Sasajima J; Tanno S; Koizumi K; Nakano Y; Habiro A; Chiba A; Fujii T; Sugiyama Y; Nakamura K; Nishikawa T; Mizukami Y; Okumura T; Kohgo Y
Gan To Kagaku Ryoho; 2009 Oct; 36(10):1657-61. PubMed ID: 19838023
[TBL] [Abstract][Full Text] [Related]
13. [A case of pancreatic acinar cell carcinoma with a giant liver metastasis successfully treated with combination of gemcitabine and peroral S-1].
Nishimizu T; Minemura M; Kajiura S; Tokimitsu Y; Itaya Y; Yamawaki H; Kawai K; Tajiri K; Nakayama Y; Hosokawa A; Takahara T; Yasumura S; Shimizu S; Fukuoka J; Ishizawa S; Sawasaki T; Yanagisawa A; Sugiyama T
Gan To Kagaku Ryoho; 2011 Feb; 38(2):309-12. PubMed ID: 21368502
[TBL] [Abstract][Full Text] [Related]
14. [Clinical benefit of full-dose gemcitabine for advanced pancreatic cancer refractory to S-1+gemcitabine].
Hachisuka H; Takahashi M; Kushima A; Nakamoto T; Takahashi K; Iwamura Y; Wakata M; Nagano K; Nakajima T; Nunomura M; Araki K
Gan To Kagaku Ryoho; 2013 May; 40(5):639-42. PubMed ID: 23863590
[TBL] [Abstract][Full Text] [Related]
15. [Effective combination chemotherapy with gemcitabine hydrochloride, S-1 and nedaplatin for recurrent pancreatic cancer--a case report].
Tokairin Y; Iida M; Yamazaki S
Gan To Kagaku Ryoho; 2008 Nov; 35(12):2123-5. PubMed ID: 19106544
[TBL] [Abstract][Full Text] [Related]
16. [Two cases of pancreatic cancer with multiple liver metastases treated with radical treatment after successful treatment with gemcitabine plus S-1 therapy].
Sato Y; Tsuchiya Y; Aizawa M; Nomura T; Nashimoto A
Gan To Kagaku Ryoho; 2014 Sep; 41(9):1151-4. PubMed ID: 25248901
[TBL] [Abstract][Full Text] [Related]
17. Prospective multicenter study to investigate the introduction rate of second-line S-1 in gemcitabine-refractory unresectable pancreatic cancer.
Kawashima H; Itoh A; Ohno E; Nakamura M; Miyahara R; Ohmiya N; Hara K; Kanamori A; Itoh T; Taki T; Hirai T; Hashimoto S; Takeda K; Goto H; Hirooka Y
Cancer Chemother Pharmacol; 2011 Sep; 68(3):677-83. PubMed ID: 21132496
[TBL] [Abstract][Full Text] [Related]
18. [A partial response to S-1 as second-line chemotherapy in a patient with unresectable pancreatic cancer].
Egawa T; Ohashi M; Ito Y; Mihara K; Takahashi T; Hayashi S; Nagashima A
Gan To Kagaku Ryoho; 2009 Nov; 36(12):2422-4. PubMed ID: 20037443
[TBL] [Abstract][Full Text] [Related]
19. [A case of advanced pancreatic cancer successfully treated by combined chemotherapy of S-1 and gemcitabine].
Kawasaki H; Kukita K; Mizushima Y; Hirata K
Gan To Kagaku Ryoho; 2008 Jul; 35(7):1239-42. PubMed ID: 18633272
[TBL] [Abstract][Full Text] [Related]
20. Plasma pharmacokinetics after combined therapy of gemcitabine and oral S-1 for unresectable pancreatic cancer.
Nakata B; Amano R; Nakao S; Tamura T; Shinto O; Hirakawa T; Okita Y; Yamada N; Hirakawa K
J Exp Clin Cancer Res; 2010 Feb; 29(1):15. PubMed ID: 20181235
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
